These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31386063)

  • 1. Genotyping low-grade gliomas among Hispanics.
    Cardona AF; Rojas L; Wills B; Behaine J; Jiménez E; Hakim F; Useche N; Bermúdez S; Arrieta O; Mejía JA; Ramón JF; Carranza H; Vargas C; Otero J; González D; Rodríguez J; Ortiz LD; Cifuentes H; Balaña C
    Neurooncol Pract; 2016 Sep; 3(3):164-172. PubMed ID: 31386063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system.
    Figarella-Branger D; Bouvier C; de Paula AM; Mokhtari K; Colin C; Loundou A; Chinot O; Metellus P
    J Neurooncol; 2012 Nov; 110(2):205-13. PubMed ID: 22890969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of
    Huang SP; Chan YC; Huang SY; Lin YF
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers.
    Figarella-Branger D; Maues de Paula A; Colin C; Bouvier C
    Rev Neurol (Paris); 2011 Oct; 167(10):683-90. PubMed ID: 21889777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study.
    Ang SYL; Lee L; See AAQ; Ang TY; Ang BT; King NKK
    BMC Cancer; 2020 Jan; 20(1):79. PubMed ID: 32005184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
    Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
    Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?
    Franceschi E; Tosoni A; De Biase D; Lamberti G; Danieli D; Pizzolitto S; Zunarelli E; Visani M; Di Oto E; Mura A; Minichillo S; Scafati C; Asioli S; Paccapelo A; Bartolini S; Brandes AA
    Oncologist; 2019 May; 24(5):664-670. PubMed ID: 30777895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach.
    Rajmohan KS; Sugur HS; Shwetha SD; Ramesh A; Thennarasu K; Pandey P; Arivazhagan A; Santosh V
    J Clin Pathol; 2016 Aug; 69(8):686-94. PubMed ID: 26743027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
    Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
    Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas.
    Ducray F; Mokhtari K; Crinière E; Idbaih A; Marie Y; Dehais C; Paris S; Carpentier C; Dieme MJ; Adam C; Hoang-Xuan K; Duyckaerts C; Delattre JY; Sanson M
    Eur J Cancer; 2011 Mar; 47(5):802-8. PubMed ID: 21194923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular-genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort.
    Hayashi S; Sasaki H; Kimura T; Abe T; Nakamura T; Kitamura Y; Miwa T; Kameyama K; Hirose Y; Yoshida K
    Oncotarget; 2015 Jun; 6(18):15871-81. PubMed ID: 25991674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
    Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
    J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular markers in low-grade gliomas: predictive or prognostic?
    Hartmann C; Hentschel B; Tatagiba M; Schramm J; Schnell O; Seidel C; Stein R; Reifenberger G; Pietsch T; von Deimling A; Loeffler M; Weller M;
    Clin Cancer Res; 2011 Jul; 17(13):4588-99. PubMed ID: 21558404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
    World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
    Karsy M; Guan J; Huang LE
    J Neurosurg; 2019 Jan; 130(1):56-66. PubMed ID: 29547090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
    Ogura R; Tsukamoto Y; Natsumeda M; Isogawa M; Aoki H; Kobayashi T; Yoshida S; Okamoto K; Takahashi H; Fujii Y; Kakita A
    Neuropathology; 2015 Aug; 35(4):324-35. PubMed ID: 25950388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.